With scores of scientists exploring dozens of ideas on how to detect or even cure ovarian cancer, the Rivkin Center is on the cutting edge of ovarian cancer research. We keep a finger on the pulse of research from the world over, and we’ll share it with you here, along with news and insights from our staff, Scientific Board, other experts in the field, and patients and family members affected by ovarian cancer.

New study extends benefit of Rucaparib PARP inhibitor to women with BRCA defects in tumors who do not carry inherited BRCA mutations

A study published in Lancet Oncology by Dr. Iain McNeish (2016 Rivkin Pilot Award Recipient), Dr. Elizabeth Swisher (2009 Rivkin Pilot Award Recipient), and colleagues provided key data that helped fuel the FDA’s recent approval of rucaparib for ovarian cancers with defects in the BRCA1 and BRCA2 genes in women previously treated with two or more chemotherapies.

Shop Makers Mercantile During Ovarian Cancer Awareness Month

Long-term Rivkin Center partner, Skacel Collection, Inc. is launching a special promotion this September through their Makers Mercantile site! In honor of Ovarian Cancer Awareness Month and inspired by the Skacel family’s commitment to supporting ovarian cancer research, the company is offering a 10% discount off your ENTIRE purchase, which results in a 10% donation […]

X